Piramal Pharma Limited (PPLPHARMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Piramal Pharma Limited (PPLPHARMA) has a cash flow conversion efficiency ratio of 0.110x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs8.90 Billion ≈ $96.22 Million USD) by net assets (Rs80.74 Billion ≈ $873.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PPLPHARMA equity financing ratio to measure how much of total assets are equity-financed.
Piramal Pharma Limited - Cash Flow Conversion Efficiency Trend (2021–2026)
This chart illustrates how Piramal Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Piramal Pharma Limited cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Piramal Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Piramal Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SOLVAY S.A. UNSP.ADR/1/10
F:SOL0
|
0.080x |
|
Fujian Sunner Development Co Ltd
SHE:002299
|
0.145x |
|
Shanghai Construction Group Co Ltd
SHG:600170
|
0.053x |
|
Virtu Financial, Inc.
NASDAQ:VIRT
|
-0.040x |
|
Central Depository Services (India) Limited
NSE:CDSL
|
0.188x |
|
Organización Soriana S. A. B. de C. V
MX:SORIANAB
|
0.047x |
|
Redington Limited
NSE:REDINGTON
|
0.071x |
|
Gerdau S.A
SA:GGBR3
|
0.028x |
Annual Cash Flow Conversion Efficiency for Piramal Pharma Limited (2021–2026)
The table below shows the annual cash flow conversion efficiency of Piramal Pharma Limited from 2021 to 2026. For the full company profile with market capitalisation and key ratios, see Piramal Pharma Limited market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs81.63 Billion ≈ $882.76 Million |
Rs14.00 Billion ≈ $151.36 Million |
0.171x | +56.13% |
| 2025-03-31 | Rs81.25 Billion ≈ $878.74 Million |
Rs8.92 Billion ≈ $96.50 Million |
0.110x | -13.51% |
| 2024-03-31 | Rs79.11 Billion ≈ $855.58 Million |
Rs10.05 Billion ≈ $108.64 Million |
0.127x | +77.74% |
| 2023-03-31 | Rs67.73 Billion ≈ $732.53 Million |
Rs4.84 Billion ≈ $52.33 Million |
0.071x | +87.46% |
| 2022-03-31 | Rs66.97 Billion ≈ $724.21 Million |
Rs2.55 Billion ≈ $27.60 Million |
0.038x | +350.09% |
| 2021-03-31 | Rs41.01 Billion ≈ $443.47 Million |
Rs347.20 Million ≈ $3.75 Million |
0.008x | -- |
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, i… Read more